CCRM Nordic Announces Formation of New Scientific Advisory Board to Propel Regenerative Medicine Innovations

CCRM Nordic, a leader in the development and commercialization of regenerative medicine, today unveiled its new Scientific Advisory Board (SAB). The board features distinguished scientists with expertise spanning many critical areas within Advanced Therapy Medicinal Products (ATMPs).

The SAB members are:

• Ass. Prof. Anna Pasetto, Director of the Center for Advanced Cell Therapy at Oslo University Hospital and Associate Professor at the University of Oslo. Specializes in cell therapy techniques.
• Prof. Johan Rockberg, Professor at KTH Royal Institute of Technology, expert in gene therapy vehicles and bi-specific protein therapeutics. Co-founder of Strike Pharma.
• Ass. Prof. Agnete Kirkeby, Group leader at the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) at University of Copenhagen, focused on stem cell therapies for neurodegenerative diseases. Co-leader of the STEM-PD clinical trial.
• Prof. Heli Skottman, Professor at Tampere University, developing stem cell-based tools for ocular repair. Founder and CTO of StemSight.
• Dr. Pontus Blomberg, Director of the Vecura GMP facility and Karolinska Center for Cell Therapy, specializes in clinical cell therapy processes.

Anna Falk, CSO of CCRM Nordic, remarked, “The formation of our Scientific Advisory Board is a pivotal development in our quest to spearhead the commercialization of ATMPs. The collective expertise of these distinguished members will greatly enrich our scientific and strategic endeavors.”

For more information, please contact: Anna Falk, anna.falk@ccrmnordic.se

About CCRM Nordic:

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.

About CCRM:

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca